Verve Therapeutics jumps on report Eli Lilly eyeing co in up to $1.3 billion deal
ReutersJun 17, 2025 8:31 AM
** Genetic medicines co Verve Therapeutics' VERV.O shares jump 82.6% to $11.45 in choppy premarket trading
** Eli Lilly LLY.N is in talks to buy VERV for up to $1.3 billion to expand its experimental drug pipeline, Financial Times reports
** The deal could be announced as early as this week, provided talks stay on track - FT, citing people familiar with the matter
** VERV up ~11% so far this year through Monday
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
BOJ June Meeting Preview: 2025 Rate Hikes Off the Table; Slowdown in Bond Purchase Cuts?
TradingKey - On Tuesday, June 17, 2025, the Bank of Japan (BOJ) will hold its monetary policy meeting. The market widely expects that the policy interest rate will remain unchanged at 0.5%. The key focus ahead of the meeting is likely to be how quickly the BOJ will reduce its pace of scaling back...TradingKey
Mon, Jun 16
[IN-DEPTH ANALYSIS] LULU: Can it Recover from the Drop?
TradingKey - Thesis Among the stocks of the twenty largest clothing companies by revenue, Lululemon has the fifth lowest forward PE ratio. With all the negative sentiment revolving around the stock, we believe their multiple should be higher.TradingKey
Mon, Jun 16
[IN-DEPTH ANALYSIS] Australia: Under the Influence of Domestic and International Factors, AUD/USD Remains Bullish in the Short Term
Following the AUD/USD exchange rate increase in April and May this year, we believe there remains upside potential for the currency pair in the short term (0-3 months).TradingKey
Mon, Jun 16
What is the Future of Stablecoins? Here are Some Stablecoin Stocks to Watch
With regulations solidifying, institutional money flowing in, and global market expansion accelerating, stablecoin-related stocks could experience unprecedented growth.TradingKey
Wed, Jun 11
Tesla Q1 2025 Earning Report Review: Autonomous Driving and Robotics Lead Future Growth
TradingKey - Tesla's Q1 2025 earnings results revealed short-term financial pressure, with core data lower than market expectations, and both revenue and profitability facing challenges. Against the backdrop of sales and profit pressure, Musk remains confident in Tesla's future.TradingKey
Wed, Apr 23
Tradingkey
